Lantus Solostar Injection, Solution
Product Images NDC 50090-1398

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Lantus Solostar (NDC 50090-1398). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Lantus 01)

Chemical structure diagram of the active ingredient insulin glargine, showing its amino acid sequence with A and B chains, disulfide bridges, and the C-terminal extension of the B-chain.*

FDA Label Image

Figure (Lantus 02)

A line graph comparing glucose infusion rates (mg/kg/min) over time (hours) after subcutaneous injection for insulin glargine and NPH insulin. Insulin glargine shows a sustained, relatively stable infusion rate up to 24 hours, while NPH insulin displays a sharper peak around 4 hours before declining. The graph includes symbols marking the end of the observation period.*

FDA Label Image

Figure (Lantus 03)

An instructional illustration showing hands removing the cap from a vial, likely depicting preparation for drawing a subcutaneous injection. The image is a simple black and white line drawing without text.*

FDA Label Image

Figure (Lantus 04)

An instructional illustration showing a person peeling a protective seal off the top of a glass vial. The image focuses on the hands and the vial, indicating a step in preparing an injection.*

FDA Label Image

Figure (Lantus 05)

An instructional illustration showing a hand holding a syringe with a needle, preparing to inject a liquid. One hand holds the syringe barrel while the other hand adjusts the plunger. The image depicts a step commonly associated with administering a subcutaneous injection.*

FDA Label Image

Figure (Lantus 06)

An instructional illustration showing a hand holding a syringe and drawing injection solution from a vial. The image depicts the proper technique for filling a syringe, with an arrow indicating the direction of needle insertion into the vial.*

FDA Label Image

Figure (Lantus 07)

An instructional illustration showing a hand manipulating an insulin pen device. The image demonstrates holding the pen and pressing a button or knob at the end, indicated by an arrow, likely depicting the operation to release insulin from the pen for injection.*

FDA Label Image

Figure (Lantus 08)

An instructional illustration showing hands preparing a syringe by drawing liquid from a vial. One hand holds the syringe plunger being pulled back to draw fluid, while the other hand stabilizes the vial.*

FDA Label Image

Figure (Lantus 09)

An instructional diagram showing a person's hand holding a syringe and an insulin pen, preparing to perform a subcutaneous injection. The illustration guides on injection technique likely relevant to Lantus Solostar insulin glargine injection, solution.*

FDA Label Image

Figure (Lantus 10)

An instructional line drawing showing a close-up of hands preparing a subcutaneous injection, demonstrating how to pinch the skin and insert the needle at an angle. This figure is likely part of usage instructions for Lantus Solostar insulin glargine injection.*

FDA Label Image

Figure (Lantus 11)

An illustration of the Lantus SoloStar injection pen components for subcutaneous use. It shows the pen cap, a labeled pen needle with protective seals on the outer and inner needle caps, and the pen body with visible insulin reservoir, rubber seal, dosage selector, dose window, and injection button. The pen body is labeled with the proprietary name Lantus SoloStar.*

FDA Label Image

Figure (Lantus 12)

An instructional illustration showing how to attach a cap to the Lantus SoloStar injection pen. The image depicts hands handling the pen and cap, demonstrating the proper alignment and placement of the cap onto the pen device before use.*

FDA Label Image

Figure (Lantus 13)

An instructional diagram showing a hand holding an insulin injection pen with a connected needle. A red X crosses out the image, indicating an incorrect handling or usage method of the insulin glargine injection device.*

FDA Label Image

Figure (Lantus 14)

Instructional diagram showing a hand twisting the cap off a Lantus SoloStar injection pen. The image demonstrates the step to remove the protective cap before use, with an arrow indicating the direction to turn the cap upwards and away from the pen body.*

FDA Label Image

Figure (Lantus 15)

Instructional illustration showing the parts of an insulin injection pen related to needle use. It depicts a needle cap labeled 'Keep' and a needle base labeled 'Discard' with arrows indicating the removal process from the pen. The pen is shown with a close-up of the injection end where the needle attaches.*

FDA Label Image

Figure (Lantus 16)

An instructional diagram showing a hand preparing a syringe for injection. The image highlights the removal of air bubbles from the syringe by tapping and expelling air through the needle, with a close-up view of the needle tip and a drop of liquid at the tip.*

FDA Label Image

Figure (Lantus 17)

An instructional illustration depicting a hand adjusting the dose on a Lantus Solostar insulin glargine injection pen, showing a dosage dial with numbers and an arrow indicating the direction to turn for dose setting.*

FDA Label Image

Figure (Lantus 18)

Illustration showing a hand holding a Lantus SoloStar insulin pen injecting insulin through a needle, with an arrow indicating the direction of injection for subcutaneous administration.*

FDA Label Image

Figure (Lantus 19)

An instructional illustration showing how to use the Lantus Solostar injection pen. It depicts a hand holding the pen with an arrow indicating the direction to press or push, and a timer icon showing "10 secs" to indicate holding the injection for 10 seconds.*

FDA Label Image

Label Image (Lbl500901398)

Label for Lantus Solostar insulin glargine injection, solution, 100 units/mL, distributed by A-S Medication Solutions. It shows lot number, storage instructions (store at 36 to 46 degrees F, do not freeze), and packaging details of 5 prefilled pens of 3 mL each. The NDC code is 50090-1398.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.